Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes.
Staudacher DL, Putz V, Heger L, Reinöhl J, Hortmann M, Zelenkofske SL, Becker RC, Rusconi CP, Bode C, Ahrens I. Staudacher DL, et al. Among authors: rusconi cp. Eur Heart J Acute Cardiovasc Care. 2019 Sep;8(6):520-526. doi: 10.1177/2048872617703065. Epub 2017 Apr 13. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 28403626
Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.
Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA, Alexander JH, Rusconi CP, Becker RC. Povsic TJ, et al. Among authors: rusconi cp. J Thromb Thrombolysis. 2011 Jul;32(1):21-31. doi: 10.1007/s11239-011-0588-3. J Thromb Thrombolysis. 2011. PMID: 21503856 Clinical Trial.
Factor IXa inhibitors as novel anticoagulants.
Howard EL, Becker KC, Rusconi CP, Becker RC. Howard EL, et al. Among authors: rusconi cp. Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):722-7. doi: 10.1161/01.ATV.0000259363.91070.f1. Epub 2007 Feb 1. Arterioscler Thromb Vasc Biol. 2007. PMID: 17272750 Review.
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. Cohen MG, et al. Among authors: rusconi cp. Circulation. 2010 Aug 10;122(6):614-22. doi: 10.1161/CIRCULATIONAHA.109.927756. Epub 2010 Jul 26. Circulation. 2010. PMID: 20660806 Clinical Trial.
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.
Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, Alexander JH. Povsic TJ, et al. Among authors: rusconi cp. Am Heart J. 2011 Feb;161(2):261-268.e1-2. doi: 10.1016/j.ahj.2010.10.022. Am Heart J. 2011. PMID: 21315207 Clinical Trial.
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.
Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC; RADAR Investigators. Povsic TJ, et al. Among authors: rusconi cp. Eur Heart J. 2011 Oct;32(19):2412-9. doi: 10.1093/eurheartj/ehr179. Epub 2011 Jun 30. Eur Heart J. 2011. PMID: 21724623 Clinical Trial.
43 results